Oncology journal October issue

Delaying the Use of High-Dose Melphalan With Stem Cell Rescue in Multiple Myeloma Is Ready for Prime Time 

Dickran Kazandjian, MD, and Ola Landgren, MD, PhD

  Abstract: The significant advances made in the treatment of multiple myeloma (MM) have allowed for a paradigm shift away from the early use of high-dose […]

From Recent Issues

Phosphoinositide 3-Kinase Inhibition in the Treatment of Hormone Receptor–Positive Breast Cancer

  H&O  Which patients are eligible for treatment with alpelisib?  HR  One of the major advances this year in treating hormone receptor (HR)-positive breast cancer has […]

A Rational Approach to the Development of Drug Combinations in Thoracic Oncology

H&O  What is the typical approach to the development of drug combinations in oncology? DRC  In clinical trials, drug combinations can reflect several scenarios. A trial […]

Management of Rare Epithelial Ovarian Cancers 

  H&O  What percentage of ovarian cancers are epithelial? DG  Approximately 90% of all invasive ovarian cancers are epithelial. The other 2 major categories of invasive […]

Supplements

A New Strategy for Uncontrollable Bleeding After Treatment With Rivaroxaban or Apixaban

Abstract: Anticoagulants are used in several settings to reduce the risk of thromboembolic events, but they can be associated with severe complications, such as potentially fatal bleeding. […]

Highlights in Lymphoma From the 2019 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2019 ASCO Annual Meeting • May 31-June 4, 2019 • Chicago, Illinois Brentuximab Vedotin With Chemotherapy for Stage 3/4 […]

Highlights in Chronic Lymphocytic Leukemia From the 2019 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2019 ASCO Annual Meeting • May 31-June 4, 2019 • Chicago, Illinois Final Analysis From RESONATE: Six-Year Follow-Up in […]